Predict your next investment

Corporation
HEALTHCARE | Drug Development
modernatx.com

See what CB Insights has to offer

Total Raised

$1.961B

Investors Count

21

Deal Terms

9

Investments

3

Moderna Therapeutics Funding, Moderna Therapeutics Valuation & Moderna Therapeutics Revenue

14 Fundings

Moderna Therapeutics's latest funding round was a IPO for $604.34M on December 7, 2018.

Moderna Therapeutics's latest post-money valuation is from December 2018.

Sign up for a free 30-day trial to see Moderna Therapeutics's valuations in December 2018 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

12/7/2018

IPO

$604.34M

$99M

$0.00B

((9.99x))

FY 1234

4

5/4/2018

Corporate Minority - III

$125M

$0.00B

((9.99x))

FY 1234

6

2/1/2018

Series G

$500M

$0.00B

((9.99x))

FY 1234

17

8/24/2016

Series F

$99M

$0.00B

((9.99x))

FY 1234

10

8/10/2016

Corporate Minority - II

$99M

$0.00B

((9.99x))

FY 1234

10

Date

12/7/2018

5/4/2018

2/1/2018

8/24/2016

8/10/2016

Round

IPO

Corporate Minority - III

Series G

Series F

Corporate Minority - II

Amount

$604.34M

$125M

$500M

$99M

$99M

Investors

Valuation

$99M

Revenue

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

Sources

4

6

17

10

10

Financials

Income Statement

Income Statement

12/31/2020

12/31/2019

12/31/2018

Total Sales (or Revenue)

$99M

$99M

$99M

Cost of Goods Sold (COGS) including Depreciation and Ammortization

$99M

$99M

$99M

Gross Income

$99M

$99M

$99M

SG&A Excluding Other

$99M

$99M

$99M

Other Operating Expense

$99M

$99M

$99M

EBIT (Operating Income)

$99M

$99M

$99M

Non-Operating Income (Expense)

$99M

$99M

$99M

Interest Expense

$99M

$99M

$99M

Usual Expense

$99M

$99M

$99M

Pretax Income

$99M

$99M

$99M

Income Taxes

$99M

$99M

$99M

Equity in Earnings of Affiliates Income

$99M

$99M

$99M

Other After Tax Adjustments

$99M

$99M

$99M

Consolidated Net Income

$99M

$99M

$99M

Minority Interest Expense

$99M

$99M

$99M

Net Income From Continuing Operations

$99M

$99M

$99M

Preferred Dividends

$99M

$99M

$99M

Net Income Available to Common

$99M

$99M

$99M

EPS (Recurring)

$99M

$99M

$99M

EPS - Basic - Before Extraordinaries

$99M

$99M

$99M

EPS (Diluted)

$99M

$99M

$99M

EBITDA

$99M

$99M

$99M

Stock Option Compensation Expense

$99M

$99M

$99M

Operating Lease Expense

$99M

$99M

$99M

Foreign Currency Adjustment (Net)

$99M

$99M

$99M

Income Statement

Total Sales (or Revenue)

Cost of Goods Sold (COGS) including Depreciation and Ammortization

Gross Income

SG&A Excluding Other

Other Operating Expense

EBIT (Operating Income)

Non-Operating Income (Expense)

Interest Expense

Usual Expense

Pretax Income

Income Taxes

Equity in Earnings of Affiliates Income

Other After Tax Adjustments

Consolidated Net Income

Minority Interest Expense

Net Income From Continuing Operations

Preferred Dividends

Net Income Available to Common

EPS (Recurring)

EPS - Basic - Before Extraordinaries

EPS (Diluted)

EBITDA

Stock Option Compensation Expense

Operating Lease Expense

Foreign Currency Adjustment (Net)

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2018

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Financials

Balance Sheet

Balance Sheet

12/31/2020

12/31/2019

12/31/2018

Cash & Short Term Investments

$99M

$99M

$99M

Inventories

$99M

$99M

$99M

Other Current Assets

$99M

$99M

$99M

Total Current Assets

$99M

$99M

$99M

Net Property, Plant & Equipment

$99M

$99M

$99M

Total Investments and Advances

$99M

$99M

$99M

Long-Term Note Receivable

$99M

$99M

$99M

Intangible Assets

$99M

$99M

$99M

Deferred Tax Assets

$99M

$99M

$99M

Other Assets

$99M

$99M

$99M

Total Assets

$99M

$99M

$99M

Short Term Debt (including Current Portion of Long Term Debt)

$99M

$99M

$99M

Accounts Payable

$99M

$99M

$99M

Income Tax Payable

$99M

$99M

$99M

Other Current Liabilities

$99M

$99M

$99M

Total Current Liabilities

$99M

$99M

$99M

Long Term Debt

$99M

$99M

$99M

Provision for Risks Charges

$99M

$99M

$99M

Deferred Tax Liabilities

$99M

$99M

$99M

Other Liabilities

$99M

$99M

$99M

Total Liabilities

$99M

$99M

$99M

Non-Equity Reserves

$99M

$99M

$99M

Preferred Stock - Carrying Value

$99M

$99M

$99M

Common Equity

$99M

$99M

$99M

Total Shareholders Equity

$99M

$99M

$99M

Accumulated Minority Interest

$99M

$99M

$99M

Total Equity

$99M

$99M

$99M

Total Liabilites & Stockholders Equity

$99M

$99M

$99M

Book Value Per Share

$99M

$99M

$99M

Tangible Book Value Per Share

$99M

$99M

$99M

Balance Sheet

Cash & Short Term Investments

Inventories

Other Current Assets

Total Current Assets

Net Property, Plant & Equipment

Total Investments and Advances

Long-Term Note Receivable

Intangible Assets

Deferred Tax Assets

Other Assets

Total Assets

Short Term Debt (including Current Portion of Long Term Debt)

Accounts Payable

Income Tax Payable

Other Current Liabilities

Total Current Liabilities

Long Term Debt

Provision for Risks Charges

Deferred Tax Liabilities

Other Liabilities

Total Liabilities

Non-Equity Reserves

Preferred Stock - Carrying Value

Common Equity

Total Shareholders Equity

Accumulated Minority Interest

Total Equity

Total Liabilites & Stockholders Equity

Book Value Per Share

Tangible Book Value Per Share

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2018

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Financials

Cash Flow

Cash Flow

12/31/2020

12/31/2019

12/31/2018

Net Income (Starting Line)

$99M

$99M

$99M

Depreciation

$99M

$99M

$99M

Deferred Taxes & Investment Tax Credit

$99M

$99M

$99M

Other Funds (Non Cash)

$99M

$99M

$99M

Funds from Operations

$99M

$99M

$99M

Extraordinary Item

$99M

$99M

$99M

Changes in Working Capital

$99M

$99M

$99M

Net Operating Cash Flow

$99M

$99M

$99M

Capital Expenditures

$99M

$99M

$99M

Net Assets From Acquisitions

$99M

$99M

$99M

Sale of Fixed Assets and Businesses

$99M

$99M

$99M

Purchase or Sale of Investments

$99M

$99M

$99M

Other Uses

$99M

$99M

$99M

Other Sources

$99M

$99M

$99M

Net Investing Cash Flow

$99M

$99M

$99M

Cash Dividends Paid

$99M

$99M

$99M

Change in Capital Stock

$99M

$99M

$99M

Issuance or Reduction of Debt, Net

$99M

$99M

$99M

Net Financing Active Other Cash Flow

$99M

$99M

$99M

Net Financing Cash Flow

$99M

$99M

$99M

Exchange Rate Effect

$99M

$99M

$99M

Miscellaneous Funds

$99M

$99M

$99M

Net Change in Cash

$99M

$99M

$99M

Free Cash Flow

$99M

$99M

$99M

Cash Flow

Net Income (Starting Line)

Depreciation

Deferred Taxes & Investment Tax Credit

Other Funds (Non Cash)

Funds from Operations

Extraordinary Item

Changes in Working Capital

Net Operating Cash Flow

Capital Expenditures

Net Assets From Acquisitions

Sale of Fixed Assets and Businesses

Purchase or Sale of Investments

Other Uses

Other Sources

Net Investing Cash Flow

Cash Dividends Paid

Change in Capital Stock

Issuance or Reduction of Debt, Net

Net Financing Active Other Cash Flow

Net Financing Cash Flow

Exchange Rate Effect

Miscellaneous Funds

Net Change in Cash

Free Cash Flow

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2018

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Moderna Therapeutics Deal Terms

9 Deal Terms

Moderna Therapeutics's deal structure is available for 9 funding rounds, including their IPO from December 07, 2018.

Round

IPO

Series G

Corporate Minority - II

Corporate Minority

Series E

Funding Date

$99M

$99M

$99M

$99M

$99M

Pre-Money Valuation

$99M

$99M

$99M

Post-Money Valuation

$99M

$99M

$99M

Amount Raised

$99M

$99M

$99M

$99M

$99M

Shares Authorized

Issuance Price

$99M

Dividend Rate

Liquidation Preferences

$99M

Liquidation Price

Participation

Conversion Price

Anti Dilution

$99M

General Voting

$99M

$99M

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

IPO

$99M

$99M

$99M

$99M

$99M

$99M

Series G

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Corporate Minority - II

$99M

$99M

$99M

$99M

$99M

$99M

Corporate Minority

$99M

$99M

$99M

$99M

$99M

$99M

Series E

$99M

$99M

$99M

$99M

Moderna Therapeutics Investors

21 Investors

Moderna Therapeutics has 21 investors. Merck & Co. invested in Moderna Therapeutics's Corporate Minority - III funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

1/14/2015

5/4/2018

2
Corporate Minority, Corporate Minority - III (2018)

Corporation

New Jersey

12/19/2014

2/1/2018

3
Series E, Series F (2016), Series G (2018)

Asset/Investment Management

New York

1/13/2014

8/24/2016

3
Series D, Series E (2014), Series F (2016)

Corporation

Massachusetts

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

Massachusetts

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Asset/Investment Management

Massachusetts

First funding

1/14/2015

12/19/2014

1/13/2014

00/00/0000

00/00/0000

Last Funding

5/4/2018

2/1/2018

8/24/2016

00/00/0000

00/00/0000

Investor

Subscribe to see more

Subscribe to see more

Rounds

2
Corporate Minority, Corporate Minority - III (2018)
3
Series E, Series F (2016), Series G (2018)
3
Series D, Series E (2014), Series F (2016)

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Subscribe to see more

Type

Corporation

Asset/Investment Management

Corporation

Venture Capital

Asset/Investment Management

Location

New Jersey

New York

Massachusetts

Massachusetts

Massachusetts

Moderna Therapeutics Acquisitions

8 Acquisitions

Moderna Therapeutics acquired 8 companies. Their latest acquisition was Caperna on September 14, 2017.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/14/2017

Corporate Minority

Merger

1

9/14/2017

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

9/14/2017

Spinoff / Spinout

Subscribe to see more

$99M

Subscribe to see more

10

9/14/2017

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

10/22/2015

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/14/2017

9/14/2017

9/14/2017

9/14/2017

10/22/2015

Investment Stage

Corporate Minority

Corporate Minority

Spinoff / Spinout

Corporate Minority

Corporate Minority

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

Total Funding

$99M

$99M

$99M

$99M

Note

Merger

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Moderna Therapeutics Investments

3 Investments

Moderna Therapeutics has made 3 investments. Their latest investment was in Caperna as part of their Corporate Minority on October 10, 2015.

CBI Logo

Moderna Therapeutics Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/22/2015

Corporate Minority

Caperna

Yes

1

5/12/2015

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

1/14/2014

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/22/2015

5/12/2015

1/14/2014

Round

Corporate Minority

Corporate Minority

Corporate Minority

Company

Caperna

Subscribe to see more

Subscribe to see more

Amount

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.